KIMBERLY-CLARK CORP

Kimberly‑Clark expands its Thrive waste‑diversion program while the $40B Kenvue deal faces EU scrutiny—boosting ESG appeal yet adding regulatory risk for investors.

ACCC clears Kimberly‑Clark’s $40B Kenvue takeover, but requires divesting Carefree and Stayfree brands—unlocking a global growth strategy and innovation drive.

Kimberly‑Clark wrestles rising input costs while boosting productivity—can lean manufacturing and automation preserve margins and keep investors confident?

Kimberly‑Clark reports Q1 2026 earnings: revenue beats forecast, EPS falls short due to cost pressures, warehouse fire risks supply‑chain disruptions.

Kimberly‑Clark appoints Francesco Tinto as CIO to boost “Powering Care” tech strategy, but decade‑long share decline raises investor doubts.

Kimberly‑Clark’s Q4 2025 earnings show steady growth and a 54th‑year dividend hike, positioning the consumer staples stock as a reliable income play amid market volatility.

Kimberly‑Clark’s disciplined brand‑investment and steady dividend growth make it a top‑choice consumer‑staple stock poised for upside.

Explore Kimberly‑Clark Corp’s resilience: steady consumer‑staple fundamentals amid acquisition buzz, regulatory hurdles, and mixed analyst outlooks.

Kimberly-Clark Corp has announced a $3.5 billion strategic partnership with Suzano S.A. to divest its international tissue assets and focus on higher growth and margin categories.